天士力(600535)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600535 天士力

交易中 04-23 14:34:14

{"stockData":{"symbol":"600535","market":"SH","secType":"STK","nameCN":"天士力","latestPrice":15.15,"timestamp":1713854054000,"preClose":15.29,"halted":0,"volume":11830861,"delay":0,"floatShares":1494000000,"shares":1494000000,"eps":1.6056,"marketStatus":"交易中","marketStatusCode":2,"change":-0.14,"latestTime":"04-23 14:34:14","open":15.27,"high":15.36,"low":14.9,"amount":178000000,"amplitude":0.0301,"askPrice":15.15,"askSize":144,"bidPrice":15.14,"bidSize":24,"shortable":0,"etf":0,"ttmEps":1.6056,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1713855600000},"adr":0,"adjPreClose":15.29,"symbolType":"stock","openAndCloseTimeList":[[1713835800000,1713843000000],[1713848400000,1713855600000]],"highLimit":16.82,"lowLimit":13.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1493950005,"pbRate":1.85,"roa":"--","roe":"8.75%","epsLYR":0.72,"committee":-0.481728,"marketValue":22633000000,"floatMarketCap":22633000000,"peRate":9.435725,"changeRate":-0.0092,"turnoverRate":0.0079,"status":1},"requestUrl":"/m/hq/s/600535","defaultTab":"news","newsList":[{"id":"2429794217","title":"天士力获首创证券买入评级，业绩符合预期，中药创新药有望进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2429794217","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429794217?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:03","pubTimestamp":1713783820,"startTime":"0","endTime":"0","summary":"4月22日，天士力获首创证券买入评级，近一个月天士力获得6份研报关注。研报预计2024年至2026年公司营业收入分别为91.40亿元、97.30亿元和103.54亿元，同比增速分别为5.4%、6.5%和6.4%；归母 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240422/c657147625.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429919315","title":"天士力(600535)2023年年报点评报告：产品布局丰富 业绩稳定增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429919315","media":"国海证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2429919315?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:27","pubTimestamp":1713770840,"startTime":"0","endTime":"0","summary":"事件:天士力于2024 年4 月16 日发布2023 年年度报告：2023 年公司实现营收86.74 亿元，同比增长0.42%；实现归母净利润10.71 亿元，同比增长505.34%；实现扣非归母净利润11.81 亿元，同比增长60.11%。2023 年，公司创新中药研发与重点品种二次开发快速推进，管线中19 款现代中药研发产品处于临床II、III 期研究阶段。2023 年，公司持续加大研发创新力度，加速数智中药研发进程，全年研发投入13.15 亿元，同比增长29.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221527308b44ecd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221527308b44ecd1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429990842","title":"腾讯及天士力入股干细胞治疗公司跃赛生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2429990842","media":"天眼查","top":-1,"share":"https://www.laohu8.com/m/news/2429990842?lang=zh_cn&edition=full","pubTime":"2024-04-22 13:48","pubTimestamp":1713764892,"startTime":"0","endTime":"0","summary":"天眼查App显示，近日，上海跃赛生物科技有限公司发生工商变更，新增股东腾讯旗下广西腾讯创业投资有限公司、天士力（600535）旗下绍兴天士力生物医药产业股权投资基金合伙企业（有限合伙）、浦东创投旗下上海浦东天使创业投资合伙企业（有限合伙），同时，公司注册资本由约337万人民币增至约386万人民币。上海跃赛生物科技有限公司成立于2021年6月，法定代表人为高琴琴，经营范围含细胞技术研发和应用、医学研究和试验发展、企业管理、企业管理咨询等。公开信息显示，跃赛生物一直致力于开发新一代基于人多能干细胞技术的细胞治疗药物，在研管线覆盖帕金森病和其他神经退行性疾病。不久前，该公司宣布完成超亿元A轮融资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422135648879fb5d2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429967123","title":"天士力获国海证券买入评级，产品布局丰富，业绩稳定增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2429967123","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429967123?lang=zh_cn&edition=full","pubTime":"2024-04-22 10:45","pubTimestamp":1713753900,"startTime":"0","endTime":"0","summary":"4月22日，天士力获国海证券买入评级，近一个月天士力获得5份研报关注。研报预计2024-2026年天士力营业收入为91.81、96.24、100.10亿元，归母净利润为11.34、12.14、12.84亿元。研报认为，由于公司持续聚焦核心业务，创新实力逐渐加强，产品覆盖逐渐全面，不断强化内生增长驱动。风险提示：集采降价风险，新品放量不及预期，研发进展不及预期，欧美市场销售不及预期，行业政策变动风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422104504879f0ccf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240422104504879f0ccf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429969277","title":"阿尔茨海默概念盘中拉升，天士力涨1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429969277","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429969277?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:47","pubTimestamp":1713750473,"startTime":"0","endTime":"0","summary":"04月22日，阿尔茨海默概念盘中拉升，截至09点47分，阿尔茨海默概念整体指数上涨0.67%，报1101.860点。从个股上来看，该概念的成分股中，天士力涨1.37%，恩华药业、京新药业、康弘药业涨幅居前。从资金上来看，截止发稿，阿尔茨海默概念概念主力净流入为-2478.43万，其中上海莱士受到资金热捧，主力净流入120.39万；拉长时间线来看，该板块近20日主力资金净流入-14.83亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042209475387e82500&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042209475387e82500&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428307027","title":"北向资金4月17日净卖出天士力97.89万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428307027","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428307027?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403812,"startTime":"0","endTime":"0","summary":"4月17日，北向资金减持天士力97.89万股连续7日减持。截止当日收盘，沪股通共持有天士力5269.60万股，占流通股3.52%。沪股通减持金额前五个股分别为贵州茅台、工业富联、中信银行、赛力斯、中国中免。天士力近5个交易日下跌3.00%，沪股通累计减持540.37万股；近20个交易日下跌13.08%，沪股通累计减持1380.11万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418093122878c73e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418093122878c73e5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428584579","title":"天士力(600535)：业绩符合预期 研发提质提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2428584579","media":"华泰证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2428584579?lang=zh_cn&edition=full","pubTime":"2024-04-18 00:00","pubTimestamp":1713369600,"startTime":"0","endTime":"0","summary":"2023 年收入同比基本持平、扣非净利同比增长60%公司公告2023 年实现营收86.7 亿元，归母净利润10.7亿元，扣非净利润11.8 亿元，主因中药板块收入增长及减值计提减少，扣非净利与业绩预报相符。中药：23 年平稳增长，24~25 年有望延续增势2023 年中药业务收入同比增长6.6%，毛利率同比提升2.4 pct，我们预计利润端增速显著高于收入端。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181054428b32ce5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181054428b32ce5a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428313975","title":"天士力(600535)：研发管线高效推进 经营质量稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2428313975","media":"中信建投证券股...","top":-1,"share":"https://www.laohu8.com/m/news/2428313975?lang=zh_cn&edition=full","pubTime":"2024-04-17 18:13","pubTimestamp":1713348794,"startTime":"0","endTime":"0","summary":"核心观点公司2023 年营业收入和扣非后净利润分别同比增长0.42%和60.11%，基本符合预期。23 年公司克服外部环境因素扰动，核心业务实现稳健增长；公司持续推进研发管线建设，同时经营质量稳步提升，现金分红率达到46.03%。2023 年，公司中药板块实现收入59.71 亿元，同比增长6.62%，毛利率增加2.36 个百分点至72.24%，收入、利润两端均实现提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171813178b2e6556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171813178b2e6556&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428539809","title":"天士力(600535)：符合预期 经营质量稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2428539809","media":"浙商证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2428539809?lang=zh_cn&edition=full","pubTime":"2024-04-17 15:59","pubTimestamp":1713340745,"startTime":"0","endTime":"0","summary":"投资要点事件：天士力发布2023 年年报，报告期内实现营收86.74 亿元，归母净利润10.71 亿元，扣非归母净利润11.81 亿元；单Q4 实现营收21.03亿元，归母净利润0.39 亿元，扣非归母净利润1.27亿元；业绩符合预期。经营业绩稳健增长。经营质量稳步提升。维持“买入”评级。预计2024-2026 年归母净利润13.84/15.51/17.36 亿元，同比增长29.21%/12.06%/11.96%，EPS 为0.93/1.04/1.16 元，对应PE16.08x/14.35x/12.82x。考虑到公司具有较强的品牌力和研发实力，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171559128b2de7cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171559128b2de7cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428836352","title":"远离“股市”后，天士力扭亏了","url":"https://stock-news.laohu8.com/highlight/detail?id=2428836352","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2428836352?lang=zh_cn&edition=full","pubTime":"2024-04-17 13:33","pubTimestamp":1713331996,"startTime":"0","endTime":"0","summary":"主业才是“王道”从收入来看，天士力整体增长有限。2023年，天士力的收入为86.74亿元，同比仅增长了0.42%。2023年，天士力的医药工业创收74.21亿元，同比仅增长了3.22%，较2022年增速放缓了4.19个百分点。雪上加霜的是，受到集采的冲击，天士力抗肿瘤类药物2023年仅实现了1.90亿元收入，下滑了近4成。即便如此，天士力利润却增长显著，2023年归母净利润高达10.71亿元，同比增幅高达505.34%。值得一提的是，天士力此次依旧进行了一定比例的分红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171338088b2d71bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171338088b2d71bb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428333361","title":"国投证券给予天士力买入评级，扣非净利润符合预期，临床中后期研发管线储备丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2428333361","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2428333361?lang=zh_cn&edition=full","pubTime":"2024-04-17 08:26","pubTimestamp":1713313560,"startTime":"0","endTime":"0","summary":"国投证券04月17日发布研报称，给予天士力（600535.SH，最新价：14.9元）买入评级，目标价格为23.00元。评级理由主要包括：1）扣非净利润符合预期，中药主业实现稳健增长；2）透过资产负债表和现金流量表，公司经营质量提升显著。风险提示：中药材价格波动的风险，中成药集采降价的风险，研发项目失败的风险。AI点评：天士力近一个月获得3份券商研报关注，买入2家，增持1家，平均目标价为23元，与最新价14.9元相比，高8.1元，目标均价涨幅54.36%。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170828128b2c6e0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170828128b2c6e0a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427821402","title":"不沉迷炒股了！天士力扭亏，还得靠复方丹参滴丸","url":"https://stock-news.laohu8.com/highlight/detail?id=2427821402","media":"健识局","top":-1,"share":"https://www.laohu8.com/m/news/2427821402?lang=zh_cn&edition=full","pubTime":"2024-04-16 20:49","pubTimestamp":1713271756,"startTime":"0","endTime":"0","summary":"中药大品种缓慢突围这么多年下来，天士力还是依赖着复方丹参滴丸。天士力看家品种复方丹参滴丸至今遥遥领先，仍是公司的销冠。米内网数据显示，2022年，复方丹参滴丸在我国公立医疗机构终端的销售额超过30亿元。但这不影响复方丹参滴丸在国内的销售。集采并没能撼动复方丹参滴丸的地位。2022年广东联盟中成药集采中，天士力的复方丹参滴丸降幅15%中选。天士力正在抓紧给复方丹参滴丸加固护城河。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404162050448b2a7886&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404162050448b2a7886&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427699823","title":"药企年报解读｜业绩暴增逾五倍  天士力证券投资仍“拖后腿”","url":"https://stock-news.laohu8.com/highlight/detail?id=2427699823","media":"北京商报官方账号","top":-1,"share":"https://www.laohu8.com/m/news/2427699823?lang=zh_cn&edition=full","pubTime":"2024-04-16 19:43","pubTimestamp":1713267807,"startTime":"0","endTime":"0","summary":"而天士力此次业绩大增，与公允价值变动损失较上年减少不无关系。天士力在2023年陆续处置了持有的部分证券资产，迎来了业绩的回暖。扭亏为盈2023年，天士力归属净利润实现扭亏，同比增长逾五倍。医药商业板块营收下滑2023年，天士力来自医药商业的收入出现下滑，同比下滑14.21%。医药工业方面，天士力主要发力的方向为中药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161944538b2a4af2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161944538b2a4af2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427442778","title":"天士力(600535)3月31日股东户数6.07万户，较上期减少0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427442778","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427442778?lang=zh_cn&edition=full","pubTime":"2024-04-16 18:14","pubTimestamp":1713262474,"startTime":"0","endTime":"0","summary":"证券之星消息，近日天士力披露，截至2024年3月31日公司股东户数为6.07万户，较12月31日减少148.0户，减幅为0.24%。在中药行业个股中，天士力股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.25万户。从股价来看，2023年12月31日至2024年3月31日，天士力区间跌幅为5.35%，在此期间股东户数减少148.0户，减幅为0.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161816118b2a00ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161816118b2a00ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427849711","title":"东方财富证券给予天士力增持评级，2023年报点评：加速数智中药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2427849711","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2427849711?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:42","pubTimestamp":1713260566,"startTime":"0","endTime":"0","summary":"东方财富证券04月16日发布研报称，给予天士力（600535.SH，最新价：14.9元）增持评级。评级理由主要包括：1）公司归母净利润回升明显；2）加大研发投入加速数智中药研发；3）公司盈利能力获得较好恢复。风险提示：行业政策变化风险；产品质量安全风险；研发进程不达预期；原材料价格波动；AI点评：天士力近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：东方财富证券给予天士力增持评级，2023年报点评：加速数智中药研发","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161749338b29ecb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161749338b29ecb0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427813155","title":"干细胞概念盘中跳水，天士力跌4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427813155","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427813155?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:46","pubTimestamp":1713250003,"startTime":"0","endTime":"0","summary":"04月16日，干细胞概念盘中跳水，截至14点46分，干细胞概念整体指数下跌6.08%，报699.030点。从个股上来看，该概念的成分股中，天士力跌4.41%，南京新百、中源协和、正海生物跌幅居前。从资金上来看，截止发稿，干细胞概念主力净流入为-1.46亿，其中瑞茂通受到资金热捧，主力净流入268.57万；拉长时间线来看，该板块近20日主力资金净流入-13.17亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161446437a531114&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161446437a531114&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427998892","title":"开源证券维持天士力买入评级 归母净利润扭亏为盈 创新研发赋能向好发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2427998892","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2427998892?lang=zh_cn&edition=full","pubTime":"2024-04-16 13:40","pubTimestamp":1713246014,"startTime":"0","endTime":"0","summary":"开源证券04月16日发布研报称，维持天士力（600535.SH，最新价：15.04元）买入评级。评级理由主要包括：1）营收稳健增长，归母净利润扭亏；2）心脑血管、感冒发烧等领域营收增长稳健，肝病治疗产品受集采因素扰动；3）研发创新持续推进，中药、生物药、化药协同发展。风险提示：市场竞争加剧，产品研发进展不及预期，产品销售不及预期。文章来源：每日经济新闻原标题：开源证券维持天士力买入评级，归母净利润扭亏为盈，创新研发赋能向好发展","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161349068b2909af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161349068b2909af&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427894844","title":"开源证券：给予天士力买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2427894844","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427894844?lang=zh_cn&edition=full","pubTime":"2024-04-16 13:25","pubTimestamp":1713245132,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意近期对天士力进行研究并发布了研究报告《公司信息更新报告：归母净利润扭亏为盈，创新研发赋能向好发展》，本报告对天士力给出买入评级，当前股价为15.08元。天士力营收稳健增长，归母净利润扭亏，维持“买入”评级公司2023年实现营收86.74亿元；归母净利润10.71亿元；扣非归母净利润11.81亿元。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级2家，增持评级2家；过去90天内机构目标均价为20.17。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161326268782a6c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161326268782a6c2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427894841","title":"天士力(600535)2023年年报点评：内生业绩全面修复 创新中药丰收在望","url":"https://stock-news.laohu8.com/highlight/detail?id=2427894841","media":"光大证券","top":-1,"share":"https://www.laohu8.com/m/news/2427894841?lang=zh_cn&edition=full","pubTime":"2024-04-16 13:24","pubTimestamp":1713245054,"startTime":"0","endTime":"0","summary":"业绩符合市场预期。2023 年归母净利润扭亏为盈，与金融资产公允价值变动损失低于上年有关；扣非归母净利润大幅增长，主要系公司内生业绩增长以及计提的资产减值损失较上年同期减少所致。产品结构优化提振毛利率，运营效率大幅提升。创新中药丰收在望，数智科研引领行业发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161324178b28f6a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161324178b28f6a5&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2002-08-23","address":"天津市北辰区普济河东道2号(天士力现代中药城)","stockEarnings":[{"period":"1week","weight":-0.0218},{"period":"1month","weight":-0.0688},{"period":"3month","weight":0},{"period":"6month","weight":0.136},{"period":"1year","weight":0.0143},{"period":"ytd","weight":-0.1016}],"companyName":"天士力医药集团股份有限公司","boardCode":"AI0027","perCapita":"24607股","boardName":"医药制造业","registeredCapital":"149395万元","compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0987},{"period":"6month","weight":0.0237},{"period":"1year","weight":-0.0777},{"period":"ytd","weight":0.0234}],"survey":"　　天士力医药集团股份有限公司主营业务为药品的研发、生产和销售。公司产品主要有复方丹参滴丸、养血清脑颗粒、养血清脑丸、芪参益气滴丸、注射用益气复脉、水林佳等药品。公司“新医视-医者新视界”私域生态体系获得2023数字医疗创新峰会（DPIS）金营奖——私域营销类金奖；公司营销SaaS平台和“新医视”私域运营解决方案同时获评“2023爱分析·医疗医药数字化创新奖”。","serverTime":1713854057891,"listedPrice":14.7,"stockholders":"60711人(较上一季度减少0.24%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天士力(600535)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天士力(600535)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天士力,600535,天士力股票,天士力股票老虎,天士力股票老虎国际,天士力行情,天士力股票行情,天士力股价,天士力股市,天士力股票价格,天士力股票交易,天士力股票购买,天士力股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天士力(600535)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天士力(600535)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}